Navigation Links
PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)

BOSTON, Aug. 17, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year for the Pharmaceutical Industry in The Eighth Annual International Business Awards, the only global, all-encompassing business awards program honoring great performances in business.  PAREXEL was recognized for helping its global client base increase the efficiency of clinical trials, access emerging markets, and speed new medical treatments to patients.

PAREXEL was selected as Company of the Year for the Pharmaceutical Industry by an independent panel of internationally-based judges.  The Company was honored for transforming its business to deliver best-practice strategic partnering models that leverage its global resources and worldwide technology infrastructure.  PAREXEL, which announced strategic partnerships over the past year with Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck, and Pfizer, was recognized for its leadership in bringing more effectiveness to biopharmaceutical development.

"We are honored to be recognized by the judges of The International Business Awards.  This award is a tribute to the expertise of our employees who provide innovative solutions to help our clients accomplish their product development goals.  We share a vision with our clients to bring healthcare improvements to patients around the world.  All of us at PAREXEL are committed to advancing the success of the biopharmaceutical industry in our mission to prevent and cure disease," said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International.

In addition to the recognition of Company of the Year for the Pharmaceutical Industry, the DataLabs® EDC solution from Perceptive Informatics, a subsidiary of PAREXEL, was named in The International Business Awards as Distinguished Honoree in the category of "Best New Product or Service of the Year:  Computer Software – Software as a Service." This honor recognizes the Company's focus on innovation and continuous investment in the next generation of technologies to accelerate clinical development.

Winners and honorees of The International Business Awards, selected from over 3,000 entries received from organizations and individuals in more than 40 countries, were determined through two rounds of judging by close to 200 professionals worldwide.  More information about The International Business Awards can be found at

For more information about PAREXEL, visit For more information about Perceptive Informatics, visit

About The Stevie AwardsStevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service.  Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide.  Learn more about the Stevie Awards at

About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

Kim Baker/Gene CarozzaPAREXEL International

PAN CommunicationsTel: +781-434-4409

Tel: + 617-502-4300Email:


SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Wells Fargo Healthcare Conference
2. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
3. PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
4. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
7. PAREXEL Issues Updated Financial And Operational Information
8. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
9. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
10. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
11. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
Post Your Comments:
(Date:11/24/2015)... AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: ... held on December 29, 2015 at 11:00 a.m. Israel ... Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... election of Eric Paneth and Izhak Tamir to ... and Rami Skaliter as external directors; , approval of an amendment ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... . Twist Bioscience is on ...
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... InSphero ... organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating ... Ms. Aregger served on the management team and was promoted to Head ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):